Download Files:
Zandelisib
$183 – $2,750
Products Details
Product Description
– Zandelisib (ME-401) is a phosphatidylinositol 3-kinase (PI3K) inhibitor extracted from patent WO2019183226 A1, Compound Example 1. Zandelisib selectively inhibits p110δ with an IC50 of 3.5 nM. Zandelisib functions as an antineoplastic[1][2].
Web ID
– HY-109198
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C31H38F2N8O
References
– [1]Daniel P. Gold, et al. Combination therapy. WO2019183226A1.|[2]David Brown, et al. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases. WO2014055647A1.
CAS Number
– 1401436-95-0
Molecular Weight
– 576.68
Compound Purity
– 98.79
SMILES
– CN1CCC(C2=CC=CC=C2CC(NC3=NC(N4C5=CC=CC=C5N=C4C(F)F)=NC(N6CCOCC6)=N3)(C)C)CC1
Clinical Information
– Phase 3
Research Area
– Cancer
Solubility
– DMSO : 9.09 mg/mL (ultrasonic)
Target
– PI3K
Isoform
– PI3Kδ
Pathway
– PI3K/Akt/mTOR
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
